Recruiting

Advanced MRI Techniques

Sponsor:

Jonsson Comprehensive Cancer Center

Code:

NCT07339085

Conditions

Malignant Brain Neoplasm

Metastatic Malignant Neoplasm in the Brain

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Advanced Magnetic Resonance Imaging

Biospecimen Collection

Magnetic Resonance Imaging

Study Details

Brief summary:

This clinical trial studies whether advanced magnetic resonance imaging (MRI) techniques, including diffusion-relaxation correlation spectrum imaging (DR-CSI) and sodium imaging, can be used to identify the difference between brain tumors that come back after a period of improvement (recurrent) and treatment-related tissue damage (radiation necrosis \[RN\]). Radiation therapy is often used in the treatment of brain tumors. Radiation treatment response can be difficult to assess and is usually done using conventional MRI, which uses radio waves and a powerful magnet linked to a computer to create detailed pictures of areas inside the body. Current imaging techniques have a limited ability to identify the difference between recurrent brain tumor and RN due to their similar appearance on conventional MRI and overlapping clinical presentation. This makes it hard for doctors to plan the best way to treat these tumors. DR-CSI is a new MRI technique with the potential to detect microscopic tissue components with different characteristics. Sodium imaging is an MRI technique that estimates the total sodium concentration in the obtained images. It may be able to identify the small structures within the tissue of brain tumors. Advanced MRI techniques like DR-CSI and sodium imaging may be effective in identifying the difference between recurrent brain tumors and RN.

Conditions

Malignant Brain Neoplasm

Metastatic Malignant Neoplasm in the Brain

Study ID

NCT07339085

Start date

Aug 28, 2025

Status verified date

Jan, 2026

Completion date

Jul 30, 2030

Anticipated

Primary completion date

Jul 30, 2030

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age > 18 years old
  • Diagnosed with metastatic brain tumor
  • AIM 1: Scheduled for surgical resection or tissue biopsy +/- laser interstitial thermal therapy (LITT)
  • AIM 2: Scheduled for SRS treatment

Exclusion Criteria:

  • Patients with contraindications to MRI, severe renal impairment
  • Patients with evidence of disseminated leptomeningeal disease

Study Design

Enrollment

42 participants

Anticipated

Allocation

Non randomized

Intervention Model

Parallel Assignment

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Aim 1 (advanced MRI)

Patients undergo advanced DR-CSI and sodium MRI over 30 minutes prior to SOC surgical resection or biopsy. Patients also undergo clinical MRI and tissue sample collection on study.

experimental: Aim 2 (advanced MRI)

Patients undergo advanced DR-CSI and sodium MRI over 30 minutes before SRS and 2 weeks, 3 months, and 6 months post-SRS. Patients also undergo clinical MRI on study.

Interventions

Advanced Magnetic Resonance Imaging

Undergo advanced DR-CSI and sodium MRI

Biospecimen Collection

Undergo tissue sample collection

Magnetic Resonance Imaging

Undergo clinical MRI

Primary outcome measure

  • Imaging features of recurrent brain metastasis (rBM) and radiation necrosis (RN) (Aim 1) [ Time Frame: At time of advanced magnetic resonance imaging: Baseline ]
  • Stereotacic imaging-guided biopsies and correlation with tissue quantifications (Aim 1) [ Time Frame: Up to completion of surgery ]
  • Early imaging changes as predictors of clinical outcomes (Aim 2) [ Time Frame: At baseline and 2 weeks, 3 months, and 6 months post-stereotactic radiosurgery (SRS) ]

Central Contacts and Locations

Locations

UCLA / Jonsson Comprehensive Cancer Center

Recruiting

Los Angeles, California, United States, 90095

Contacts

Principal Investigator:

Jingwen Yao

More Information

Sponsor

Jonsson Comprehensive Cancer Center

Last update posted

Jan 15, 2026

Last verified

Jan, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Jonsson Comprehensive Cancer Center on 2026-01-15.